Literature DB >> 20720485

The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis.

Nikolas Wanahita1, Jennifer Chen, Sripal Bangalore, Kunal Shah, Maurice Rachko, Craig I Coleman, Paul Schweitzer.   

Abstract

The objective of this study was to assess whether statin therapy is associated with a reduction in ventricular tachyarrhythmias. Statins have been shown to be beneficial beyond their cholesterol-lowering effects. These pleiotropic effects have been implicated in the protection against atrial fibrillation and the reduction in appropriate implantable cardioverter-defibrillator therapy in patients with coronary artery disease. This meta-analysis was conducted to evaluate whether statins were associated with a reduction in ventricular tachyarrhythmias in patients with coronary artery disease or nonischemic cardiomyopathy. The Medline and Cochrane databases were searched for studies in human subjects published in the English language between 1985 and February 2010. Studies were included in our analysis if they provided data regarding the association between the use of statins and the incidence of ventricular tachycardia/ventricular fibrillation (VT/VF) in patients with coronary artery disease or nonischemic cardiomyopathy. The occurrence of ventricular arrhythmias was defined as the VT/VF occurrence or appropriate implantable cardioverter-defibrillator therapy for VT/VF. Of the 166 identified articles, nine prospective studies with 150,953 patients enrolled met our inclusion criteria and were included in this analysis. Using a random effects model, statin therapy was associated with a 31% reduction in the risk of VT/VF when compared with the group not on statin therapy (pooled relative risk = 0.69, 95% confidence interval, 0.58-0.83; heterogeneity I² = 57.3%). There was a low likelihood of publication bias in this analysis (Egger's test P = 0.957). Statin use in patients with coronary artery disease or nonischemic cardiomyopathy is associated with a 31% reduction in the development of ventricular tachyarrhythmias.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 20720485     DOI: 10.1097/MJT.0b013e3181e9087a

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  6 in total

1.  Statin therapy in patients with atypical chest pain and mild-to-moderate coronary stenosis on 64-slice multidetector coronary computed tomography; a retrospective propensity score matching analysis.

Authors:  Hyo Eun Park; Goo-Yeong Cho; Yeonyee E Yoon; Tae-Jin Youn; Eun-Ju Chun; Sang-Il Choi; Dong-Ju Choi
Journal:  Eur Radiol       Date:  2013-06-26       Impact factor: 5.315

Review 2.  Epidemiology of ventricular tachyarrhythmia : Any changes in the past decades?

Authors:  Benjamin Jong-Ming Pang; Martin Stephen Green
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-05-08

3.  Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.

Authors:  M Bláha; H Vlcková; L Nováková; D Solichová; P Solich; M Lánská; J Malý; V Bláha
Journal:  J Biomed Biotechnol       Date:  2010-11-07

4.  Effects of Statin on Arrhythmia and Heart Rate Variability in Healthy Persons With 48-Hour Sleep Deprivation.

Authors:  Wei Ren Chen; Hong Bin Liu; Yuan Sha; Yang Shi; Hao Wang; Da Wei Yin; Yun Dai Chen; Xiang Min Shi
Journal:  J Am Heart Assoc       Date:  2016-10-31       Impact factor: 5.501

Review 5.  Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress.

Authors:  Katarina Andelova; Barbara Szeiffova Bacova; Matus Sykora; Peter Hlivak; Miroslav Barancik; Narcis Tribulova
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

6.  Human electronegative low-density lipoprotein modulates cardiac repolarization via LOX-1-mediated alteration of sarcolemmal ion channels.

Authors:  An-Sheng Lee; Yutao Xi; Chin-Hu Lai; Wei-Yu Chen; Hsien-Yu Peng; Hua-Chen Chan; Chu-Huang Chen; Kuan-Cheng Chang
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.